PTBP1 and Parkinson disease: In the first in vivo model by Qian et al. (2020), decreasing the level of PTBP1 using either ASOs or shRNA resulted in the restoration of striatal neurons which subsequently increased striatal dopamine, resulting in improved motor symptoms in the 6-hydroxydopamine (6-OHDA) PD mouse model [25].